Contrast developer Guerbet and IBM Watson Health have signed an agreement to develop and commercialize artificial intelligence (AI) software for diagnosing prostate cancer.
Anne Le Grand, general manager of the Imaging, Life Sciences, and Oncology unit at IBM Watson Health (left), with Yves L'Epine, PhD, CEO of Guerbet (right). Image courtesy of IBM Watson Health.In July 2018, Guerbet and IBM announced their decision to collaborate on developing AI software for liver cancer diagnostics. Their latest agreement is geared toward developing a tool that uses AI to detect, segment, characterize, and monitor prostate lesions on MRI scans over time.
The two companies aim to have their AI tool support radiologists and oncologists not only in diagnosing prostate cancer as early as possible but also in deciding on the most appropriate therapeutic strategy.
They also plan to make the AI tool compatible with most PACS for direct integration into existing workflows.
